Compare Amgen Inc. (AMGN) vs Johnson & Johnson (JNJ) Stock

Amgen Inc. (AMGN) offers the better valuation at 27.3x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc. (AMGN) is the cheapest at 27.3x versus Johnson & Johnson at 42.9x. On forward P/E, Amgen Inc. is actually cheaper at 17.3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Amgen Inc. wins at 5.89x versus Johnson & Johnson's 38.22x.

Over the past 5 years, Amgen Inc. (AMGN) delivered a total return of +89.7%, compared to +70.8% for Johnson & Johnson (JNJ). A $10,000 investment in AMGN five years ago would be worth approximately $19K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AMGN returned +221.6% versus JNJ's +175.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Amgen Inc.'s 0.45β — meaning AMGN is approximately 711% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

Amgen Inc. (AMGN) is the more profitable company, earning 21.0% net margin versus 15.8% for Johnson & Johnson — meaning it keeps 21.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 40.5% versus 24.9% for JNJ. At the gross margin level — before operating expenses — AMGN leads at 82.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Amgen Inc. (AMGN) is the more undervalued stock at a PEG of 5.89x versus Johnson & Johnson's 38.22x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Amgen Inc. (AMGN) trades at 17.3x forward P/E versus 21.5x for Johnson & Johnson — 4.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: -7.7% to $229.33.

In this comparison, JNJ (2.0% yield) pays a dividend. AMGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, AMGN: +221.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. JNJ pays a dividend while AMGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.